Assessment of coagulation profiles among sudanese psychiatric patients under antipsychotic drugs attending Hassan Allob Mental Hospital, Gezira State, Sudan (2020)

Khalid Abdelsamea Mohamedahmed; Amna Siddig Abdallah; Albadawi Abdebagi Talha; Amin Omer Ibrahim Abbas; Asaad Ma. Babker

doi:10.53730/ijhs.v6nS2.5419

Authors

Khalid Abdelsamea Mohamedahmed Department of Hematology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan & Department of Immunology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan
Amna Siddig Abdallah Department of Hematology, Faculty of Medical Laboratory Sciences, University of Gezira, Wad Medani, Sudan
Albadawi Abdebagi Talha Department of Clinical Laboratory Sciences, Jouf University, Saudi Arabia
Amin Omer Ibrahim Abbas Department of Clinical Medicine, Faculty of Medicine, Alrayan Colleges - Saudi Arabia
Asaad Ma. Babker
azad.88@hotmail.com
Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman, UAE

Keywords:

PT, INR, APTT, antipsychotic drugs, psychiatric disorder, Sudan

Abstract

Background: Psychiatric disorder is a mental illness diagnosed by a mental health professional that greatly disorders thinking. A psychotropic drug is a chemical substance that crosses the blood brain barrier (BBB) and acts primarily upon the central nervous system (CNS), where it affects brain function, resulting in change in perception, mood, consciousness, cognition, and behavior. It causes changes in platelet function, plasma coagulation, or fibrinolysis seemed more likely to be responsible for the increase in thrombotic events. Objectives: The aim of this study was to assess the coagulation profiles [Prothrombin Time (PT), International Normalize Ratio (INR), Activated Partial Thromboplastin Time (APTT)] in psychiatric patients under antipsychotic drug administration. Methodology: This is a case-control hospital-based study carried out in Hassan Allob Mental Hospital, Gezira State, Sudan from January to September 2020. A total of 50 psychiatric patients under antipsychotic drug administration as cases (35.52 ± 11.64 years) and 50 normal healthy individuals as controls (32.68 ± 4.85 years) participated in this study. Two ml of venous blood samples were collected from all participants in trisodium citrate container. Coagulation profiles (PT, INR, and APTT) were measured using a Coatron M4 coagulometer. SPSS computer program (v 22.0) was used for data analysis.

Downloads

Download data is not yet available.

References

Gross G and Huber G. The history of the basic symptoms concept. Acta Clinica Croatica. 2010, 49: 47-59.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Global Health Metrics. 2018, 392(10159): P1789-1858. doi.org/10.1016/S0140-6736(18)32279-7

Zornberg GL and Jick H. Antipsychotic Drugs used and the Risk of First-time Idiopathic Venous Thromboembolism: A Case Control Study. Lancet.2000, 356(9237):1219-1223. doi: 10.1016/S0140-6736(00)02784-7.

Roser M and Ritchie H. Burden of Disease. Published online at OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/burden-of-disease' [Online Resource]. 2021.

Lopez AD; Mathers CD; Ezzati M; Jamison DT; Murray CJL. Global Burden of Disease and Risk Factors. The International Bank for Reconstruction and Development / The World Bank; New York: Oxford University Press. 2006. ISBN-10: 0-8213-6262-3.

Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual Research Review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015, 56(3): 345-365. doi: 10.1111/jcpp.12381.

Salah TT, Abdelrahman A, Lien L, Eide AH, Martinez P, Hauff E. The mental health of internally displaced persons: an epidemiological study of adults in two settlements in Central Sudan. Int J Soc Psychiatry. 2013, 59(8): 782–788. doi: 10.1177/0020764012456810.

Allison DB and Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001, 62(7): 22-31. PMID: 11346192.

Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013, 64: 393-406. doi: 10.1146/annurev-med-050911-161504.

Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: result of a cross-sectional nationwide survey patients with Schizophrenia. BMC Psychiatry. 2012, 12:20. doi: 10.1186/1471-244X-12-20.

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Donkery C, Mohr P, Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophreneia. CNS drugs. 2006, 20(5): 389-409. doi: 10.2165/00023210-200620050-00004.

Tripp AC. Nonfatal pulmonary embolus associated with clozapine treatment: a case series. Gen Hosp Psychiatry. 2011, 33(1):85.e5-6. doi: 10.1016/j.genhosppsych.2010.11.010.

Liperoti R and Gambassi G. Antipsychotics and the risk of venous thromboembolism. BMJ. 2010, 341:c4216. doi: 10.1136/bmj.c4216..

Ray WA, Chung CP, Murray KT, Hall K, Stein CM. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009, 360(3):225-235. doi: 10.1056/NEJMoa0806994.

Hägg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Saftey. 2009, 8(5):537-547. doi: 10.1517/14740330903117271

Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, Mimura M. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics. 2014, 55(1):69-75. doi: 10.1016/j.psym.2013.04.001.

Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Lancu L; Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J affect Disord. 2012, 136(1-2): 99-103. doi: 10.1016/j.jad.2011.08.013.

Masopust J, Malý R, Vališ M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci. 2012, 66(7):541-552. doi: 10.1111/pcn.12001.

Bain BJ; Bates I; Laffan M; Lewis S. Dacie and Lewis practical haematology. (11th edition): Churchill Livingstone, London. 2011, Pp:394-411.

Mohammed SE. Determination of Coagulation Profile among Patients under Antipsychotic Drugs. (M. Sc. degree dissertation, University of Shendi. http://hdl.handle.net/123456789/821).

Afolabi OI, Adedire OA, Oke OT, Omisakin CT, Esan AJ. Coagulation Activities of Patients on Psychotropic Drugs in Nigeria. American Journal of Medical Sciences and Medicine. 2014, 2 (2): 41-43. doi: 10.12691/ajmsm-2-2-3

Eldaw MFM. (2019). Estimation of Prothrombin and Activated Prothrombin Time among Sudanese Patients Taking Antipsychotic Drugs in Khartoum State. (M. Sc. degree dissertation, Sudan University of Science and Technology. http://repository.sustech.edu/handle/123456789/24981).

Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, Varma AO. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979, 91(2):194-199. doi: 10.7326/0003-4819-91-2-194.